W. Jerry Liu, M.D.
Senior Vice President, Clinical Development

Dr. W. Jerry Liu brings to Atom Bioscience more than 20 years of experience in industry clinical research and drug development. After obtaining his medical degree from Peking University, Health Sciences Center, Dr. Liu completed his residency training in surgery at Peking Union Medical College Hospital. He then studied in the US and obtained MS degrees in Molecular and Cellular Biology and Mathematical Computer Science. Following his post-graduate training, he started his career in Clinical Research/Drug development. He has extensive working experience in early and late phase clinical development across several different therapeutic areas including autoimmune/inflammatory diseases, oncology and neurology. Prior to joining Atom Bioscience, Dr. Liu was Executive Medical Director at Horizon Therapeutics as the Clinical Lead for TEPEZZA for its post US approval activities. These efforts included  increasing global regulatory approval, expanding into new chronic TED sector, and developing new formulations and pipelines that enhance the value propositions of the TEPEZZA. Prior to Horizon, Dr. Liu was at Celgene and BMS. He also led the Phase 2/3 clinical studies for ozanimod for Crohn’s disease and ulcerative colitis, and the successful NDA and approval of ozanimod for UC, and initiated its pediatric clinical programs in IBD. In his earlier career stage, Dr. Liu also led clinical development at SanBio for its cell therapy for stroke and brain injury, and development of botulinum toxin products for neurological and aesthetical indication at Ipsen and Allergan. Dr. Liu also led early development programs for Alzheimer’s disease and the PML risk characterization and management of Tysabri for MS patients and associated interactions with regulatory agencies, while at Elan Pharmaceuticals.